At ANTG although we are focused on developing the best possible cannabinoid products, we believe that improving the health and wellbeing of patients goes beyond this. That’s why we are committed to investing in research and development.
We continually invest in science, research and development in-house. By prioritising research, we have the power to discover the full potential of cannabinoid medicines in preventing and treating diseases and improving lives.
We understand that a strong partnership with clinicians and researchers is crucial to expanding the industry and helping people. And so we partner with key universities to undertake cannabis research and support their clinical trial programs.
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
The results from an Australian national online survey was released last month into the use of cannabis as a self-management strategy for endometriosis. The survey aimed to determine the occurrence, tolerance and effectiveness of cannabis use for Australian women with endometriosis.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We currently have a research partnership with the Hunter Medical Research Institute, a partner of the University of Newcastle. For more information about how to become a research partner please contact us.